All questionsDosing and administration: Trodelvy (sacituzumab govitecan-hziy) in metastatic triple-negative breast cancer9 questions · 6 sourcesDosingWhat is the TRODELVY dose and treatment schedule?“The recommended dosage of TRODELVY as a single agent or in combination with pembrolizumab is 10 mg/kg intravenously on Days 1 and 8 of each 21-day cycle until disease progression or unacceptable toxicity Do not administer TRODELVY at dosages greater than 10 mg/kg Administer TRODELVY as an intravenous infusion Do NOT substitute TRODELVY for or use with other drugs containing irinotecan or its active metabolite, SN-38 21-day cycles Observe patients during the infusion and for at least 30 minutes following the infusion for signs or symptoms of infusion-related reactions.” (opens the source at this quote in a new tab)CopyFlagWhat is the maximum dose of TRODELVY?“Do not administer TRODELVY at doses greater than 10 mg/kg.” (opens the source at this quote in a new tab)CopyFlagHow should the TRODELVY dose be modified for side effects?“Do not reescalate the TRODELVY dose after a dose reduction for adverse reactions has been made.” (opens the source at this quote in a new tab)CopyFlag“Table 1: Dosage Reduction Levels Dose Reduction* Dosage and Schedule First Reduce to 7.5 mg/kg Second Reduce to 5 mg/kg *Permanently discontinue TRODELVY in patients unable to tolerate 5 mg/kg.” (opens the source at this quote in a new tab)CopyFlag“Dose modifications for adverse reactions1 Adverse reactions Severity Dose modification Neutropenia Grade 3–4 neutropenia (absolute neutrophil count [ANC] <1000/mm3) or febrile neutropenia Withhold TRODELVY until ANC ≥1500/mm3 for Day 1 dose or ANC ≥1000/mm3 for Day 8 dose Administer G-CSF during treatment as clinically indicated Reduce by 1 dose level for each occurrence of febrile neutropenia or prolonged Grade 3–4 neutropenia, or permanently discontinue according to the dosage reduction levels information above Nausea/Vomiting/ Diarrhea Grade 3–4 nausea, vomiting, or diarrhea that is not controlled with antiemetics or anti-diarrheal agents Withhold TRODELVY until resolved to ≤Grade 1 Reduce by 1 dose level with each occurrence or permanently discontinue according to the dosage reduction levels above Infusion-Related Reaction Grade 1–3 infusion-related reactions Grade 4 infusion-related reactions Slow infusion rate or interrupt the infusion Permanently discontinue TRODELVY Other Toxicities Other Grade 3–4 toxicities of any duration despite optimal medical management Withhold TRODELVY until resolved to ≤Grade 1 Reduce by 1 dose level with each occurrence or permanently discontinue according to the dosage reduction levels above” (opens the source at this quote in a new tab)CopyFlag“When administering TRODELVY in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, interrupt or discontinue one or both drugs of the combination or reduce the dose of TRODELVY to manage adverse reactions as appropriate. Refer to the Prescribing Information for pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph for recommendations on dosage interruption or discontinuation due to adverse reactions.” (opens the source at this quote in a new tab)CopyFlagNote: The dosage reduction levels appear as an image on the safety page and are quoted from the linked Prescribing Information.Treatment combinationsWho is eligible for TRODELVY plus pembrolizumab in metastatic TNBC?“Select patients for treatment of unresectable locally advanced or metastatic TNBC with TRODELVY in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, based on the tumor expression of PD-L1 as confirmed by an FDA-authorized test. Information on FDA-authorized tests is available at https://www.fda.gov/companiondiagnostics” (opens the source at this quote in a new tab)CopyFlag“In combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph for the first-line treatment of unresectable locally advanced or mTNBC whose tumors express PD-L1 [Combined Positive Score (CPS ≥10)] as determined by an FDA-authorized test” (opens the source at this quote in a new tab)CopyFlagWith TRODELVY, how long is pembrolizumab continued?“When TRODELVY is administered in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, discontinue pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, after approximately 24 months. Refer to the Prescribing Information for pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph for the recommended dosing information” (opens the source at this quote in a new tab)CopyFlagPreparationHow should TRODELVY vials be stored?“Store vials in a refrigerator at 2 °C to 8 °C (36 °F to 46 °F) in the original carton to protect from light until time of reconstitution. Do not freeze.” (opens the source at this quote in a new tab)CopyFlagHow is a TRODELVY vial reconstituted?“Using a sterile syringe, slowly inject 20 mL of 0.9% Sodium Chloride Injection, USP, into each 180 mg TRODELVY vial Each vial contains overfill to compensate for liquid loss during preparation and after reconstitution The total resulting volume delivers a concentration of 10 mg/mL Gently swirl vials and allow to dissolve for up to 15 minutes. Do not shake Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit The solution should be free of visible particulates, clear, and yellow Do not use the reconstituted solution if it is cloudy or discolored Use reconstituted TRODELVY immediately to prepare a diluted TRODELVY infusion solution” (opens the source at this quote in a new tab)CopyFlagThis passage is in a collapsed section of the page; select: ReconstitutionNote: Covers vial reconstitution; dilution and administration steps are in the linked reconstitution guide.AdministrationWhat premedications are recommended before each TRODELVY infusion?“Prior to each dose of TRODELVY, premedication for prevention of infusion reactions and of chemotherapy-induced nausea and vomiting (CINV) is recommended. • Premedicate with antipyretics, H1 and H2 blockers prior to infusion, and corticosteroids may be used for patients who had prior infusion reactions. • Premedicate with a 2 or 3 drug combination regimen (e.g., dexamethasone with either a 5-HT3 receptor antagonist or an NK1 receptor antagonist, as well as other drugs as indicated).” (opens the source at this quote in a new tab)CopyFlagHow long does a TRODELVY infusion take?“First infusion: Administer over 3 hours. Observe patients during the infusion and for at least 30 minutes following the initial dose, for signs or symptoms of infusion-related reactions • Second and subsequent infusions: Administer over 1 to 2 hours if prior infusions were tolerated. Observe patients during the infusion and for at least 30 minutes after infusion” (opens the source at this quote in a new tab)CopyFlag